Vividion Therapeutics is a biopharmaceutical company that utilizes novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. Their platform combines chemoproteomics and covalent chemistry to identify and develop small molecule drugs for diseases with unmet medical needs. Vividion operates as a wholly owned, independently operated subsidiary of Bayer AG.